2368219-35-4
2368219-35-4
Chemical Structure
Domvanalimab
Synonym(s): AB154
- CAS No.: 2368219-35-4
- Formula:N/A
- Molecular Weight:(145.12 kDa)
SMILES: [Domvanalimab]
Biological Activity: Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Domvanalimab | 98.62% | Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dolgin E. Antibody engineers seek optimal drug targeting TIGIT checkpoint. Nat Biotechnol. 2020 Sep;38(9):1007-1009. [Content Brief]
- [2]. Zhang Y, et al. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res. 2019 Aug;29(8):609-627. [Content Brief]
- [3]. Anderson A E, et al. Characterization of AB154, a humanized anti-TIGIT antibody, for use in combination studies. Cancer Research, 2019, 79(13_Supplement): 1557-1557.
